🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06506227
Starting soon Not applicable

Research on Key Technologies for Risk Prediction and Precise Diagnosis and Treatment of AIS Based on Epigene-phenotype

NCT06506227 · tracked via the Priya Life Science China tracker
Sponsor
The First Affiliated Hospital of Zhejiang Chinese Medical University
Phase
Not applicable
Started
2024-09-01
Last updated
2024-07-17

Condition(s) studied

Adolescent Idiopathic Scoliosis

Investigational drug(s) / intervention(s)

Low risk experimental groupMedium risk experimental groupHigh risk experimental groupControl group COBB 10-20°Control group COBB 20-45°Control group COBB >45°Experimental group (AIS group)Control group (healthy control)Controlled follow-up before and after AIS

Low risk experimental group: Guiding + Manipulation + Traditional Chinese Medicine

Medium risk experimental group: Guiding + Manipulation + Traditional Chinese Medicine + Specific Exercise Therapy + Orthopedic Braces

High risk experimental group: Guiding + Manipulation + Traditional Chinese Medicine + Specific Exercise Therapy + Orthopedic Braces + Specialized Inpatient Rehabilitation

Control group COBB 10-20°: Specific Exercise Therapy

Control group COBB 20-45°: Orthopedic Braces + Specific Exercise Therapy

Control group COBB >45°: Orthopedic Braces + Specific Exercise Therapy + Recommended Surgery

Experimental group (AIS group): Molecular marker exploration and validation

Control group (healthy control): Molecular marker exploration and validation

Controlled follow-up before and after AIS: Construction and validation of AIS risk prediction model completed

Study summary

Mining AIS biomarkers, elucidating the new mechanism of AIS pathogenicity, constructing risk prediction models, optimizing AIS precise diagnosis and treatment techniques, formulating precise diagnosis and treatment protocols and technical specifications for AIS combined with Chinese and Western medicine with independent intellectual property rights, and realizing the full coverage of Zhejiang Province by the end of 2026, so as to form the "Zhejiang experience" of AIS diagnosis and treatment.

Eligibility

Sex
ALL
Min age
10 Years
Max age
18 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Patients diagnosed with AIS;② Sex is not limited, age 10-18 years old; ③ Those who sign the informed consent and can cooperate with follow-up visits; ④ Those who can cooperate with X-ray, chemical test, genetic test and other examination and evaluation for the measurement of relevant indexes. Exclusion Criteria: * Subjects with spine-related diseases such as Marfan's syndrome; * Subjects with previous ankylosing spondylitis, spinal neurofibroma, spinal tuberculosis, spinal trauma and other spine-related diseases; * Subjects with combined serious medical diseases and psychiatric patients; * Those with ECOG score \> 2, which may have an impact on the study results; * Those who are affected by external factors such as economy, individualized differences, etc., so that they cannot complete the study.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Prokin balance apparatus Hangzhou Zhejiang

More The First Affiliated Hospital of Zhejiang Chinese Medical University trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06506227 on ClinicalTrials.gov ↗ ← All trials in China